Online inquiry

IVTScrip™ mRNA-Anti-MS4A1, AT-004(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3355MR)

This product GTTS-WQ3355MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets MS4A1 gene. The antibody can be applied in Canine B-cell lymphoma research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Caninized
RefSeq NM_001048028.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 485430
UniProt ID Q3C2E2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MS4A1, AT-004(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ3355MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9424MR IVTScrip™ mRNA-Anti-KLRC1, IPH-2201(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA IPH-2201
GTTS-WQ14965MR IVTScrip™ mRNA-Anti-IL17A, SHR-1314(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SHR-1314
GTTS-WQ13423MR IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PRO132365
GTTS-WQ10823MR IVTScrip™ mRNA-Anti-PD-L1&TGFBR2, M7824(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA M7824
GTTS-WQ2504MR IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG 212
GTTS-WQ14357MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RG7716
GTTS-WQ9638MR IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA JNJ-64007957
GTTS-WQ3575MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1112623(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BAY 1112623
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW